Pfizer's aggressive mergers and acquisitions combined with in-house research and development have driven its growth portfolio to generate $3.1 billion in revenues in the first quarter of 2026, a 22% operational increase year-over-year. The risk from loss of exclusivity is reduced due to a delayed generic entry for Vyndamax until mid-2031, supporting management's forecast of high single-digit revenue growth over five years starting in 2029. While Pfizer's intermediate-term performance may fluctuate, its cost-saving initiatives, strong interest coverage, and sustainable dividends create a compelling investment case. The company’s discounted valuation and attractive dividend yields compared to peers facing similar patent challenges make it a great buy for investors willing to wait for eventual re-rating.
